SLC16A1 and cancer: To conclude the issue of brain toxicity of MCT1 and MCT4 inhibitors, we should acknowledge that MCT1 inhibitors have been used in clinical research in humans, while MCT4 inhibitors have been used in preclinical research and animal studies and both constitute a promising chemotherapy for drug-resistant cancer [33].